I-O Drugs: Key to the Cancer Moonshot?

PRE-RECORDED WEBINAR
 

 

Please complete the form below to view the webinar recording. 

Name *
Name
Communication Preferences
Thank you for your interest in Context Matters. You will receive future communications. To opt-out, check the box below.

Checkpoint inhibitor immuno-oncology (I-O) treatments, widely considered as one the most promising breakthroughs in drug development, are a focus of the Cancer Moonshot initiative. But are these new therapies getting reimbursed and what are the challenges they face in gaining market access?

This webinar takes a data-driven look at the key challenges facing I-O drugs including:

  • Cost and value
  • Interpretation of clinical efficacy evidence
  • Restrictions issued by HTA agencies

 

Context Matters, (A Decision Resources Group Company)  provides health economics data and technology solutions designed to help biopharmaceutical organizations gain market access with optimally valued therapies.